The emergence of forward Aaron Nesmith as a defensive stopper certainly helped the Pacers improve last season and they that ...

The Coelho Center for Disability Law, Policy and Innovation held a grand opening ceremony on Wednesday, Oct. 16, celebrating ...

This approval was based on findings from the LIBRETTO-531 trial, which assessed treatment with Retevmo ... The main area of interest for researchers conducting this trial was progression-free survival ...

The approval was based on the Libretto-531 study, which showed significant ... with patients receiving selpercatinib showing superior progression-free survival compared to those treated with ...

As recently as a couple months ago, NFL scouts shared feedback about Alabama quarterback Jalen Milroe that pegged him as a Day 3 prospect, with the eventual outlook as a a backup or developmental ...

It found that adding the drug nivolumab to what's known as AVD therapy (doxorubicin/Adriamycin, vinblastine, and dacarbazine) ...

1 Findings from the phase 3 LIBRETTO-531 trial (NCT04211337) support this regulatory decision as selpercatinib improved progression-free survival (PFS) vs physician's choice of cabozantinib (Cabometyx ...

Now, the agency is converting the previous accelerated approval to a full approval based on results from the Phase III LIBRETTO-531 trial, in which patients ... Caprelsa (vandetanib). The median ...

Occupation/company: Managing Director of Retirement Plan Services at Trust Point Inc. Family: Parents: Roger and Sheila Fruit ...

Village Medical and The COPD Foundation today announced a webinar to support patients through Medicare Annual Enrollment ...

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping ...